Bagsværd, Denmark, 26 March 2015 - Novo Nordisk today announced that the company has decided to submit the prespecified interim analysis of DEVOTE as part of a Class II Resubmission of the New Drug Applications (NDAs) of Tresiba® and Ryzodeg® to the US Food and Drug Administration (FDA). The resubmission is expected to take place within the next month.For further information
| Media: | ||
| Mette Kruse Danielsen | +45 3079 3883 | [email protected] |
| Ken Inchausti (US) | +1 609 514 8316 | [email protected] |
| Investors: | ||
| Kasper Roseeuw Poulsen | +45 3079 4303 | [email protected] |
| Melanie Raouzeos | +45 3075 3479 | [email protected] |
| Daniel Bohsen | +45 3079 6376 | [email protected] |
| Frank Daniel Mersebach (US) | +1 609 235 8567 | [email protected] |
Company Announcement No 23 / 2015